Hugel, Inc. (KOSDAQ:145020)
South Korea
· Delayed Price · Currency is KRW 249,500
-12,000 (-4.59%)
At close: Mar 9, 2026
Hugel Revenue
In the year 2025, Hugel had annual revenue of 425.10B KRW with 13.95% growth. Hugel had revenue of 119.10B in the quarter ending December 31, 2025, with 21.27% growth.
Revenue
425.10B
Revenue Growth
+13.95%
P/S Ratio
6.34
Revenue / Employee
715.66M
Employees
594
Market Cap
2,694.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 425.10B | 52.05B | 13.95% |
| Dec 31, 2024 | 373.05B | 53.35B | 16.69% |
| Dec 31, 2023 | 319.70B | 38.02B | 13.50% |
| Dec 31, 2022 | 281.68B | 49.82B | 21.49% |
| Dec 31, 2021 | 231.86B | 20.82B | 9.87% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orum Therapeutics | 25.48M |
| SK bioscience | 624.03B |
| PharmaResearch | 496.03B |
| D&D Pharmatech | 8.36B |
| OliX Pharmaceuticals | 10.18B |
| Chabiotech | 1,197.69B |
| Voronoi | 7.49B |
| Peptron | 6.19B |